Late Breaking Abstract Parallel Session 2

Nov 10 2025
Convention Center: Hall A (General Session), Concourse Level
5:00 PM - 6:30 PM
Live Streamed
Captured

World Class Speakers

Gideon M Hirschfield, FRCP, PhD
Abstract Presenter

Gideon M Hirschfield, FRCP, PhD

Toronto General Hospital
Mazen Noureddin
Abstract Presenter

Mazen Noureddin

Houston Research Institute and Houston Methodist Hospital
Amreen Dinani, MD FRCPC
Moderator

Amreen Dinani, MD FRCPC

Duke University School of Medicine
Raymond T Chung, MD, FAASLD
Moderator

Raymond T Chung, MD, FAASLD

Massachusetts General Hospital

Description

Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

Presentations

5:00 PM - 5:15 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

Safety and Preliminary Efficacy of GST-HG131, a First-in-class Oral HBsAg Inhibitor in Chronic Hepatitis B – Phase 2 Trial Data

Gideon M Hirschfield, FRCP, PhD , Abstract Presenter
5:15 PM - 5:30 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With Primary Biliary Cholangitis Treated With Seladelpar: Results From the ASSURE Study up to 30 Months

Gideon M Hirschfield, FRCP, PhD , Abstract Presenter
5:30 PM - 5:45 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

Efficacy and safety of libevitug (HH-003) in patients with chronic hepatitis D

Gideon M Hirschfield, FRCP, PhD , Abstract Presenter
5:45 PM - 6:00 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

PBGENE-HBV, a first-in-class gene editing therapy for chronic hepatitis B, demonstrates safety and antiviral activity in early cohorts

Gideon M Hirschfield, FRCP, PhD , Abstract Presenter
6:00 PM - 6:15 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

Efficacy of 24-week peginterferon alpha-2b retreatment in interferon-experienced chronic hepatitis B patients with favorable initial response

Gideon M Hirschfield, FRCP, PhD , Abstract Presenter
6:15 PM - 6:30 PM
Aug 05 2026
Convention Center - Hall A (General Session), Concourse Level

Once-monthly Efimosfermin Alfa for Up to 48 Weeks in Metabolic Dysfunction-Associated Steatohepatitis with F2/F3 Fibrosis: Results from a Phase 2, Open-Label Extension Study

Mazen Noureddin , Abstract Presenter

Objectives

  • Review findings from recent clinical trials related to treatments for hepatitis, MASH, and PBC.